Self-assembling synthetic proteins
The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
1. A recombinant synthetic protein, comprising:
a monomeric sequence that is able to assemble into stable homo-multimers, wherein the monomeric polypeptide sequence includes
a Cholera Toxin β (CTB) subunit, wherein the CTB subunit includes missense mutations T1F, P2T, Q3D, N4I, M37I, A38I, I39L, I40V, T41N, T78S, E79N, A80S, A95S, A102V, and N103R, relative to a wildtype CTB amino acid sequence (SEQ ID NO: 18),
a peptide spacer selected from the group consisting of SSG (SEQ ID NO: 5), SSGGG (SEQ ID NO: 6), SGG (SEQ ID NO: 7), GGSGG (SEQ ID NO: 8), GGGGS (SEQ ID NO: 9), SSGGGSGGSSG (SEQ ID NO: 10), GGSGGTSGGGSG (SEQ ID NO: 11), SGGTSGGGGSGG (SEQ ID NO: 12), GGSGGTSGGGGSGG (SEQ ID NO: 13), SSGGGSGGSSG (SEQ ID NO: 14), SSGGGGSGGGSSG (SEQ ID NO: 15), SSGGGSGGSSGGG (SEQ ID NO: 16), and SSGGGGSGGGSSGGG (SEQ ID NO: 17), and
a polypeptide including a growth factor, or part thereof, selected from the group consisting of IGF-1, IGF-2, FGF1, FGF2, TGF-α, TGF-β, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EGF, HGF, BMP's, PDL1 and IL-1, IL-2, IL-3, IL-4, IL-5, and IL-6, wherein the part thereof includes a neutralizing domain of the growth factor,
wherein the polypeptide is separated from the CTB subunit by the peptide spacer.
2. The recombinant synthetic protein according to claim 1 , wherein the CTB subunit includes SEQ ID NO:1.
3. The recombinant synthetic protein according to claim 1 , wherein the CTB subunit further includes a missense mutation selected from the group consisting of L8I, A10G, F25L, A32V, N44G, V82I, and combinations thereof.
4. The recombinant synthetic protein according to claim 1 , wherein the growth factor, or part thereof, is TGF or EGF.
5. The recombinant synthetic protein according to claim 1 , wherein the growth factor, or part thereof, is a human self-protein growth factor, or part thereof.
6. The recombinant synthetic protein according to claim 1 , wherein the polypeptide includes at least two different growth factors, or parts thereof.
7. The recombinant synthetic protein according to claim 1 , wherein the polypeptide includes a full length, or part thereof, of one or more growth factors as a single domain or as two or more multiple repeats.
8. The recombinant synthetic protein according claim 7 , wherein the polypeptide includes a neutralizing domain of one or more growth factors as a single domain or as two or more multiple repeats.
9. The recombinant synthetic protein according to claim 1 , wherein the recombinant synthetic protein includes SEQ ID NO:1 or SEQ ID NO:2.